Browse News
Filter News
Found 12 articles
-
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
4/20/2023
Orphalan SA today announces the commercial launch in the US of Cuvrior™, a new trientine tetrahydrochloride (TETA-4HCl).
-
PANTHERx® Rare Announces Release of CUVRIOR™ (trientine tetrahydrochloride) to Treat Wilson Disease
4/20/2023
PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.
-
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”)
7/26/2022
Orphalan SA (“Orphalan” or “the Company”), an international orphan drug development and commercialization company, today announces the enrolment of the first five patients into the International Wilson's Disease Patient Registry (“iWD Registry”), the first global registry of patients with Wilson’s Disease.
-
An experimental AstraZeneca drug for Wilson disease hit the mark in a Phase III study in which the drug, ALXN1840, was able to mobilize copper three times greater than standard-of-care.
-
FDA Approves Orphalan's CUVRIOR™ (trientine tetrahydrochloride), the first treatment for Wilson's disease in over five decades
5/4/2022
Brand Institute is proud to announce working with rare disease specialist, Orphalan, in developing the brand name CUVRIOR™, approved by the United States Food and Drug Administration on April 28, 2022.
-
Orphalan announced the FDA has granted full approval to Cuvrior (trientine tetrahydrochloride) for the treatment of Wilson’s Disease, a rare genetic disorder.
-
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
5/2/2022
Orphalan SA today announces approval of Cuvrior™, a new salt of trientine (trientine tetrahydrochloride) by the United States Food and Drug Administration (FDA). Cuvrior™ is approved for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine.
-
Orphalan strengthens its management team with two key appointments
2/1/2022
Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan diseases, announces two new appointments to the management team.
-
Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease
9/2/2021
Orphalan announces FDA acceptance for filing of New Drug Application for trientine tetrahydrochloride for the treatment of Wilson’s Disease
-
Orphalan Announces Positive Top Line Data with Trientine Tetrahydrochloride for Maintenance Patients with Wilson’s Disease
6/25/2021
Orphalan SA is a company that identifies, develops and delivers innovative treatments to patients with rare diseases.
-
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
5/26/2021
Dr. Amin Has Served as an Independent Director Since 2015 and Succeeds Jonathan Peacock Following Mr. Peacock’s Retirement from the Company’s Board